JMDC Inc
TSE:4483
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (26.1), the stock would be worth ¥5 178.54 (48% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 17.7 | ¥3 510 |
0%
|
| 3-Year Average | 26.1 | ¥5 178.54 |
+48%
|
| 5-Year Average | 34.9 | ¥6 926.41 |
+97%
|
| Industry Average | 8.3 | ¥1 642.41 |
-53%
|
| Country Average | 8.7 | ¥1 718.41 |
-51%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
¥279.5B
|
/ |
Jan 2026
¥13.8B
|
= |
|
|
¥279.5B
|
/ |
Mar 2026
¥14.5B
|
= |
|
|
¥279.5B
|
/ |
Mar 2027
¥17.6B
|
= |
|
|
¥279.5B
|
/ |
Mar 2028
¥21.4B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
|
JMDC Inc
TSE:4483
|
229.7B JPY | 17.7 | 27.9 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 21.9 | 53.1 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
27.7B USD | 21.2 | 30.4 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
15.1B AUD | 78 | 63 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 10.1 | 20.8 | |
| SE |
|
Sectra AB
STO:SECT B
|
51.1B SEK | -131.6 | 95 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
5.1B USD | 15.8 | 44.6 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.5B USD | 15 | 18.9 | |
| IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
245.4B INR | 24.3 | 36.8 | |
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
19.2B CNY | -121.8 | -62.4 | |
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR | 267.9 | -328 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 6.7 |
| Median | 8.7 |
| 70th Percentile | 12.2 |
| Max | 214 699 781.2 |
Other Multiples
JMDC Inc
Glance View
Amidst the complex intersection of healthcare and technology, JMDC Inc. has carved a unique niche by harnessing the power of big data to improve healthcare outcomes and efficiency. Founded in Japan, the company stands as a beacon in the health informatics sector, meticulously collecting and analyzing health-related data drawn from a variety of sources, including medical claims, health screenings, and electronic health records. By transforming this extensive data trove into actionable insights, JMDC offers healthcare providers, pharmaceutical companies, and insurance firms the analytics they need to make informed decisions. Key to JMDC's operation is its commitment to safeguarding patient anonymity while extracting valuable insights that can streamline healthcare delivery, enhance pharmaceutical research, and optimize insurance underwriting. JMDC's revenue model hinges on the sale of its aggregated data and analytics solutions to a vast array of stakeholders in the medical field. Pharmaceutical companies, eager to understand drug efficacy and patient demographics better, turn to JMDC for data-driven insights that can influence drug development and marketing strategies. Insurance companies leverage JMDC's data to refine their offerings and better assess risk, ensuring competitive pricing models and improved customer satisfaction. Moreover, healthcare providers utilize this analytics backbone to enhance operational efficiency and improve patient care outcomes. Through licensing agreements and subscription-based services, JMDC effectively monetizes its data resources, achieving sustained growth in an industry that increasingly values the marriage of technology and healthcare.
